Drug intelligence / Profile preview

BI 660848

Development stage: Discontinued
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

BI 660848 is a small molecule drug initially developed by C.H. Boehringer Sohn AG & Co. KG, now part of Boehringer Ingelheim GmbH. It was investigated for its potential therapeutic effects, particularly in treating nervous system diseases, including neuropathic pain. However, its development has been discontinued.

Other names: tislelizumab + cisplatin + gemcitabine + trilaciclib-Boehringer Ingelheim-neuropathic pain

Targets

TRPC4 (Transient receptor potential cation channel subfamily C member 4)TRPC5 (Transient receptor potential Canonical-5)

Beyond the preview

Go deeper on BI 660848.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 660848.

Explore the full profile